M Cazzola

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi request reprint A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Pulm Pharmacol Ther 20:556-61. 2007
  2. ncbi request reprint The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Respir Med 101:957-62. 2007
  3. doi request reprint Outcomes for COPD pharmacological trials: from lung function to biomarkers
    M Cazzola
    Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Eur Respir J 31:416-69. 2008
  4. doi request reprint Pharmacology and therapeutics of bronchodilators
    Mario Cazzola
    Universita di Roma Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier 1, 00133 Roma, Italy
    Pharmacol Rev 64:450-504. 2012
  5. pmc New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Rome, Italy
    Drug Des Devel Ther 7:1201-8. 2013
  6. ncbi request reprint Bronchodilators: current and future
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy Electronic address
    Clin Chest Med 35:191-201. 2014
  7. ncbi request reprint Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation
    Mario Cazzola
    Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina dei Sistemi, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Roma, Italy
    Expert Opin Drug Metab Toxicol 10:129-37. 2014
  8. ncbi request reprint Inhaled corticosteroids for chronic obstructive pulmonary disease
    Mario Cazzola
    University of Rome Tor Vergata, Unit of Respiratory Clinical Pharmacology, Department of System Medicine, Via Montpellier 1, 00133 Rome, Italy
    Expert Opin Pharmacother 14:2489-99. 2013
  9. doi request reprint Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 107:1417-22. 2013
  10. doi request reprint Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
    Mario Cazzola
    University of Rome Tor Vergata, Department of System Medicine, Unit of Respiratory Clinical Pharmacology, Italy
    Expert Opin Pharmacother 14:1205-14. 2013

Detail Information

Publications154 found, 100 shown here

  1. ncbi request reprint A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Pulm Pharmacol Ther 20:556-61. 2007
    ..Our results suggest that adding FSC and tiotropium may provide benefits in symptomatic patients with severe-to-very severe stable COPD...
  2. ncbi request reprint The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Respir Med 101:957-62. 2007
    ....
  3. doi request reprint Outcomes for COPD pharmacological trials: from lung function to biomarkers
    M Cazzola
    Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Eur Respir J 31:416-69. 2008
    ..Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations...
  4. doi request reprint Pharmacology and therapeutics of bronchodilators
    Mario Cazzola
    Universita di Roma Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier 1, 00133 Roma, Italy
    Pharmacol Rev 64:450-504. 2012
    ..This review will describe the pharmacology and therapeutics of old, new, and emerging classes of bronchodilator...
  5. pmc New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Rome, Italy
    Drug Des Devel Ther 7:1201-8. 2013
    ..Moreover, the question remains whether umeclidinium/vilanterol fixed-dose combination, which significantly improves FEV1, is also associated with improvements in other outcome measures that are important to COPD patients. ..
  6. ncbi request reprint Bronchodilators: current and future
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy Electronic address
    Clin Chest Med 35:191-201. 2014
    ....
  7. ncbi request reprint Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation
    Mario Cazzola
    Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina dei Sistemi, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Roma, Italy
    Expert Opin Drug Metab Toxicol 10:129-37. 2014
    ..Indacaterol is a β2-agonist with a rapid onset of action and a bronchodilating effect that lasts for 24 h...
  8. ncbi request reprint Inhaled corticosteroids for chronic obstructive pulmonary disease
    Mario Cazzola
    University of Rome Tor Vergata, Unit of Respiratory Clinical Pharmacology, Department of System Medicine, Via Montpellier 1, 00133 Rome, Italy
    Expert Opin Pharmacother 14:2489-99. 2013
    ....
  9. doi request reprint Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 107:1417-22. 2013
    ..Our data also show that underweight is significantly associated with COPD, but only in men, while being underweight apparently protects from the possibility of suffering from asthma. ..
  10. doi request reprint Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
    Mario Cazzola
    University of Rome Tor Vergata, Department of System Medicine, Unit of Respiratory Clinical Pharmacology, Italy
    Expert Opin Pharmacother 14:1205-14. 2013
    ....
  11. doi request reprint β2-agonist therapy in lung disease
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Am J Respir Crit Care Med 187:690-6. 2013
    ..Some novel once-daily β2-agonists (olodaterol, vilanterol, abediterol) are under development, mainly in combination with an inhaled corticosteroid or a long-acting antimuscarinic agent...
  12. doi request reprint Chronic treatment with indacaterol and airway response to salbutamol in stable COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of System Medicine, Rome, Italy
    Respir Med 107:848-53. 2013
    ..The results of this study support the use of salbutamol as rescue medication for rapid relief of bronchospasm in patients suffering from COPD, even when they are under regular treatment with indacaterol...
  13. doi request reprint Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease
    Mario Cazzola
    University of Rome, Department of System Medicine, Rome Tor Vergata, Italy
    Expert Opin Pharmacother 14:775-81. 2013
    ..Consequently, there is a strong interest in developing a LABA/LAMA fixed-dose combination therapy in an attempt to simplify the treatment...
  14. ncbi request reprint Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists
    Mario Cazzola
    Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina dei Sistemi, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Pulm Pharmacol Ther 26:218-28. 2013
    ..Even after publication of the 2011 update of GOLD report, some fundamental questions in the management of COPD are still open and this may weaken the applicability of these guidelines in everyday clinical practice...
  15. doi request reprint Comorbidities of asthma: current knowledge and future research needs
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Rome, Italy
    Curr Opin Pulm Med 19:36-41. 2013
    ..The prevalence of these comorbidities varies tremendously between studies. Nevertheless, it imposes a significant reflection on the need to explore the phenomenon in depth...
  16. doi request reprint Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Respir Med 107:107-11. 2013
    ....
  17. doi request reprint Comparative effectiveness of drugs for chronic obstructive pulmonary disease
    M Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Rome, Italy
    Drugs Today (Barc) 48:785-94. 2012
    ....
  18. ncbi request reprint An update on bronchodilators in Phase I and II clinical trials
    Mario Cazzola
    University of Rome Tor Vergata, Department of System Medicine, Rome, Italy
    Expert Opin Investig Drugs 21:1489-501. 2012
    ..Therefore, there is still considerable interest in finding novel classes of broncholytic drugs or, at least, in improving the existing classes of bronchodilator...
  19. doi request reprint High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Am J Respir Cell Mol Biol 47:509-16. 2012
    ..These data propose novel targets for the treatment of patients with respiratory diseases that also suffer from diabetes mellitus...
  20. ncbi request reprint Emerging anti-inflammatory strategies for COPD
    Mario Cazzola
    Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy
    Eur Respir J 40:724-41. 2012
    ..In this review, we put together a summary of the state-of-the-art development of clearly and/or potentially useful anti-inflammatory strategies in COPD...
  21. doi request reprint Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD
    Mario Cazzola
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Curr Opin Pharmacol 12:300-8. 2012
    ..Further studies are needed to produce a greater level of evidence that can support the recommendation for a more widely use of bacterial lysates as a prophylactic treatment of AECOPDs...
  22. ncbi request reprint Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Clin Drug Investig 32:147-55. 2012
    ..Bronchodilator therapy is central to the symptomatic management of chronic obstructive pulmonary disease (COPD), and treatment with short-acting bronchodilators is recommended in patients with mild COPD...
  23. doi request reprint Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 25:62-8. 2012
    ....
  24. doi request reprint Tremor and β(2)-adrenergic agents: is it a real clinical problem?
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 25:4-10. 2012
    ..Therefore, tremor is not a really important adverse effect in patients under regular treatment with a β(2)-adrenergic agonist...
  25. doi request reprint Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study
    Mario Cazzola
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 106:249-56. 2012
    ..Moreover, it shows that the diagnosis of asthma is modestly associated with the diagnosis of different CV morbidities...
  26. ncbi request reprint The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 23:257-67. 2010
    ....
  27. doi request reprint Biomarkers in COPD
    Mario Cazzola
    Department of Internal Medicine, Respiratory Clinical Pharmacology Unit, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 23:493-500. 2010
    ....
  28. doi request reprint Arformoterol tartrate in the treatment of COPD
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Expert Rev Respir Med 4:155-62. 2010
    ....
  29. ncbi request reprint Energy expenditure and impact of bronchodilators in COPD patients
    Mario Cazzola
    Division of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 104:1490-4. 2010
    ..Our study seems to indicate that tiotropium, but not formoterol, is able to reduce energy expenditure in COPD patients, although both drugs elicit significant bronchodilation and are able to increase the distance walked in 6min...
  30. ncbi request reprint Italian real-life experience of omalizumab
    M Cazzola
    Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina Interna Università di Roma Tor Vergata, Roma, Italy
    Respir Med 104:1410-6. 2010
    ..The observed reduction of asthma-related events in particularly poorly controlled patients in this Italian real-life setting is consistent with the results of other observational studies...
  31. ncbi request reprint The cardiovascular risk of tiotropium: is it real?
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, Rome, Italy
    Expert Opin Drug Saf 9:783-92. 2010
    ..In this review, we have examined whether and why an anticholinergic agent, and in particular tiotropium, might cause CV risks...
  32. doi request reprint Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study
    Mario Cazzola
    Dipartimento di Medicina Interna, Universita di Roma Tor Vergata, Via Montpellier, Rome, Italy
    Ther Adv Respir Dis 4:271-8. 2010
    ..The purpose of this study was to investigate the efficacy of a synbiotic supplementation in reducing common winter diseases in children...
  33. doi request reprint Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Pulm Pharmacol Ther 24:118-22. 2011
    ....
  34. ncbi request reprint Indacaterol for chronic obstructive pulmonary disease (COPD)
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Rehabilitative Pneumology, IRCCS, San Raffaele Pisana, Rome, Italy
    Drugs Today (Barc) 46:139-50. 2010
    ..The rapid onset of action of indacaterol, duration of bronchodilation for at least 24 hours, and an optimal safety profile make this drug an interesting and attractive weapon for its use in fight against the COPD...
  35. ncbi request reprint Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function
    Mario Cazzola
    Division of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    COPD 6:404-15. 2009
    ..Once-daily or twice-daily formoterol, added to tiotropium, are both better than tiotropium alone, but the published evidence suggests twice-daily formoterol is the best add-on option...
  36. ncbi request reprint Treating systemic effects of COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Trends Pharmacol Sci 28:544-50. 2007
    ..Nonetheless, initial data seem to indicate that drugs, such as statins, ACE inhibitors, AT1 receptor blockers and PPAR agonists, used to treat a co-morbid condition have the potential to benefit COPD patients...
  37. ncbi request reprint One hundred years of chronic obstructive pulmonary disease (COPD)
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Diseases, University of Rome Tor Vergata, Rome, Italy
    Respir Med 101:1049-65. 2007
    ..Recent studies have documented the benefits of pulmonary rehabilitation. In addition, non-invasive mechanical ventilation offers new alternatives for patients with acute or chronic failure...
  38. pmc Novel long-acting bronchodilators for COPD and asthma
    M Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Br J Pharmacol 155:291-9. 2008
    ..The advent of a successful MABA product will revolutionize the field and open the door for a new range of combination products...
  39. ncbi request reprint Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 102:1425-30. 2008
    ....
  40. doi request reprint From large clinical trials to management of COPD in the real world
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Ther Adv Respir Dis 3:39-46. 2009
    ....
  41. ncbi request reprint Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Respiratory Disease Unit, Via Montpellier 1, I 00133 Rome, Italy
    Curr Opin Investig Drugs 10:482-90. 2009
    ....
  42. doi request reprint Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone
    Mario Cazzola
    Department of Internal Medicine, University Tor Vergata, Rome, Italy
    Ther Adv Respir Dis 3:59-63. 2009
    ..This study investigated the value of adding Ismigen, a polyvalent mechanical bacterial lysate, to therapy of COPD patients (FEV(1) <60% predicted) under regular treatment with salmeterol/fluticasone (SFC)...
  43. ncbi request reprint A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 22:522-5. 2009
    ..However, these methods are not interchangeable. In moderate-to-severe airflow obstruction, dilution method tends to underestimate and body plethysmography tends to overestimate RV...
  44. ncbi request reprint Emerging inhaled bronchodilators: an update
    M Cazzola
    Dipartimento di Medicina Interna, Universita di Roma Tor Vergata, Italy
    Eur Respir J 34:757-69. 2009
    ..The present article reviews all of the most important compounds under development, describing what has been done and discussing their genuine advantage...
  45. doi request reprint Novel bronchodilators in asthma
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome Tor Vergata, Rome, Italy
    Curr Opin Pulm Med 16:6-12. 2010
    ..Because of the central role of bronchodilators in the treatment of asthma, in recent years there has been a renewed interest in the field and now once-daily bronchodilators are in development in an attempt to simplify their use...
  46. doi request reprint TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water
    Maria Gabriella Matera
    Second University of Naples, Department of Experimental Medicine, Unit of Pharmacology and Toxicology, Naples, Italy
    Pulm Pharmacol Ther 23:121-8. 2010
    ....
  47. doi request reprint The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data
    M Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Roma Tor Vergata, Roma, Italy
    Pulm Pharmacol Ther 23:135-44. 2010
    ....
  48. ncbi request reprint Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 102:321-7. 2008
    ..Moreover, the method of inactivation can affect the immunogenicity of essential antigens through denaturation. For this reason, the efficacy of bacterial immunostimulants should not only be assessed but also compared...
  49. ncbi request reprint Roflumilast in chronic obstructive pulmonary disease: evidence from large trials
    Mario Cazzola
    Unità di Farmacologia Clinica Respiratoria, Dipartimento di Medicina Interna, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Expert Opin Pharmacother 11:441-9. 2010
    ..At present roflumilast is the most advanced PDE-4 inhibitor undergoing clinical trials for COPD...
  50. ncbi request reprint Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease
    Mario Cazzola
    Associate Professor of Respiratory Medicine, Universita di Roma Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier 1, 00133 Roma, Italy
    Expert Opin Ther Targets 11:1273-86. 2007
    ....
  51. ncbi request reprint Prevalence of comorbidities in patients with chronic obstructive pulmonary disease
    Mario Cazzola
    Division of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respiration 80:112-9. 2010
    ..Chronic obstructive pulmonary disease (COPD) is associated with many comorbidities, but the percentage of COPD patients who develop comorbidities has not been clearly defined...
  52. ncbi request reprint Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome, Rome, Italy
    Expert Rev Respir Med 5:623-5. 2011
  53. doi request reprint Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008
    Mario Cazzola
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Prim Care Respir J 20:291-8. 2011
    ..To explore the trend in prescribing of drugs classified within the R03 therapeutic pharmacological subgroup (drugs for obstructive airway diseases) of the Anatomical Therapeutic Chemical (ATC) classification...
  54. doi request reprint Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi
    Mario Cazzola
    University of Rome Tor Vergata Dept of Internal Medicine, Unit of Respiratory Diseases Via Montpellier, 1 Rome 00133, Italy
    Am J Respir Cell Mol Biol 45:704-10. 2011
    ..Our results provide mechanistic evidence for the enhanced bronchoconstriction induced by LPS in human isolated airways, the contribution of Rho/Ras pathways in this LPS response, and the protective role of statins...
  55. pmc β(2) -adrenoceptor agonists: current and future direction
    Mario Cazzola
    Unit of Respiratory Clinical Pharmacology, Department of Internal Medicine, University of Rome Tor Vergata, Italy
    Br J Pharmacol 163:4-17. 2011
    ....
  56. doi request reprint Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection
    Mario Cazzola
    Dipartimento di Medicina Interna, Universita di Roma Tor Vergata, Via Montpellier 1, Rome, Italy
    Ther Adv Respir Dis 4:259-70. 2010
    ..Blood samples were collected 3 hours or 4 days postchallenge and serum levels of pro- and anti-inflammatory cytokines were measured...
  57. doi request reprint Asthma and comorbid medical illness
    M Cazzola
    Cattedra di Malattie Respiratorie, Dipartimento di Medicina Interna, Universita di Roma Tor Vergata, Via Montpellier 1, IT 00133 Rome, Italy
    Eur Respir J 38:42-9. 2011
    ..Our results indicate that asthma is weakly associated with several comorbidities, whereas its association with allergic rhinitis or GORD is stronger...
  58. ncbi request reprint Primary care of the patient with chronic obstructive pulmonary disease in Italy
    Mario Cazzola
    Department of Internal Medicine, Unit of Respiratory Diseases, University of Rome Tor Vergata, Rome, Italy
    Respir Med 103:582-8. 2009
    ..It must also be noted that, in general, patients with COPD are undertreated...
  59. doi request reprint The prevalence of asthma and COPD in Italy: a practice-based study
    Mario Cazzola
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Respir Med 105:386-91. 2011
    ..On the contrary, the OR of developing COPD became higher than 1 from 55 years old and up both in men and in women and progressively increased with age (in the group 75-84 years, it was 6.16 in men and 4.07 in women, respectively)...
  60. ncbi request reprint Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD
    M Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Naples, Italy
    Respir Med 96:790-5. 2002
    ..11 (95% CI: -1.00 to 0.79)] did not change significantly from baseline (P > 0.05). These data indicate that salmeterol is effective and safe in the treatment of acute exacerbation of COPD and support its use in this clinical condition...
  61. ncbi request reprint Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 97:453-7. 2003
    ..The results indicate that an inhaled combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid appears to be effective in improving airway limitation after acute administration in patients suffering from COPD...
  62. ncbi request reprint Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist
    M Cazzola
    Divisione di Pneumologia e Allergologia e Unità di Farmacologia Clinica Respiratoria, Ospedale A Cardarelli, Naples, Italy
    Pulm Pharmacol Ther 13:301-5. 2000
    ....
  63. ncbi request reprint Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD
    M Cazzola
    A Cardarelli Hospital, Division of Pneumology and Allergology, Naples, Italy
    Respir Med 93:909-11. 1999
    ..In any case, formoterol 24 microg alone seems sufficient to achieve the same bronchodilation induced by oxitropium 600 microg alone in most patients...
  64. ncbi request reprint Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD
    M Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, Antonio Cardarelli Hospital, Naples, Italy
    Respir Med 100:212-7. 2006
    ..Patients with severe chronic airway obstruction might suffer dangerous hypoxemia after administration of a beta-agonist despite bronchodilation...
  65. ncbi request reprint Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease
    M Cazzola
    Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A Cardarelli Hospital, Naples, Italy
    Respiration 68:452-9. 2001
    ..It has been suggested that the effect of a beta2-agonist is additive with that of a cysteinyl leukotriene 1 receptor antagonist...
  66. ncbi request reprint Additive effects of salmeterol and fluticasone or theophylline in COPD
    M Cazzola
    A Cardarelli Hospital, Division of Pneumology and Allergology and Respiratory Clinical Pharmacology Unit, Naples, Italy
    Chest 118:1576-81. 2000
    ..ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD...
  67. ncbi request reprint Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
    M Cazzola
    Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 14:41-5. 2001
    ..Again, there was no significant difference (P= 0.817) between the four active treatments. Formoterol Turbuhaler 12 microg and 24 microg caused bronchodilation as rapidly as salbutamol 400 microg and 800 microg given via pMDI...
  68. ncbi request reprint Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma
    S Centanni
    Respiratory Disease Unit, University of Milan, San Paolo Hospital, Milan, Italy
    Respiration 67:60-4. 2000
    ..The present study was designed to assess the non-pulmonary effects of a 2-week treatment with the addition of formoterol to budesonide therapy in 10 patients with mild or moderate asthma...
  69. ncbi request reprint Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Clin Ther 24:595-604. 2002
    ....
  70. doi request reprint Effects of neuraminidase on equine isolated bronchi
    M G Matera
    Department of Experimental Medicine, Second University of Naples, Naples, Italy
    Pulm Pharmacol Ther 21:624-9. 2008
    ..5 UI) significantly increased contraction induced by EFS. These results suggest that airway hyper-responsiveness that follows a viral influenza infection might be related to a dysfunction of muscarinic prejunctional receptors...
  71. ncbi request reprint An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses
    M G Matera
    Unit of Pharmacology, Department of Experimental Medicine, Second University of Naples, Naples, Italy
    Respiration 72:466-70. 2005
    ..The possibility that individual chronic obstructive pulmonary disease (COPD) patients respond better to either tiotropium or salmeterol has been suggested and an acute bronchodilator test might help to guide the choice of therapy...
  72. ncbi request reprint Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients
    Mario Cazzola
    Antonio Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
    Respir Med 99:524-8. 2005
    ..Differences between the two treatments were not statistically significant (P>0.05). The addition of second different long-acting bronchodilator to a regularly administered long-acting bronchodilator seems to be to patient's advantage...
  73. ncbi request reprint A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease
    M Cazzola
    Respiratory Clinical Pharmacology Unit, A Cardarelli Hospital, Naples
    J Chemother 9:279-84. 1997
    ..Notwithstanding its poor in vitro activity against H. influenzae, dirithromycin was fairly active against this microorganism in vivo...
  74. ncbi request reprint Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction
    M Cazzola
    Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 15:97-102. 2002
    ..559) and 15 min (Group A: P=0.526; Group B: P=0.818) post dose. No adverse events were reported during the study. Formoterol Turbuhaler has as rapid an onset of action as salbutamol pMDI when given at the recommended doses...
  75. ncbi request reprint Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, Antonio Cardarelli High Specialty Hospital, Naples, Italy
    Pulm Pharmacol Ther 19:79-89. 2006
    ....
  76. ncbi request reprint Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Pneumology, A Cardarelli Hospital, Naples, Italy
    Respiration 71:159-64. 2004
    ....
  77. ncbi request reprint Effects of cefonicid on platelet aggregation
    M Cazzola
    36th Division of Pneumology and Respiratory Allergy, A Cardarelli Hospital, Naples, Italy
    Drugs Exp Clin Res 17:105-8. 1991
    ..These findings suggest that therapeutic doses of cefonicid do not affect platelet aggregation...
  78. ncbi request reprint Evaluation of the effects of pefloxacin on platelet aggregation in vitro and ex vivo in patients suffering from chronic bronchitis
    M Cazzola
    Institute of Pharmacology and Toxicology, Medical School, II University, Naples, Italy
    J Chemother 7:38-41. 1995
    ..In the ex vivo study carried out in 10 patients, who received pefloxacin twice daily for 7-10 days as 400 mg oral dose, the drug did not influence platelet aggregation up to 24 hours after administration of the last oral dose...
  79. ncbi request reprint Pulmonary penetration of ceftazidime
    M Cazzola
    Institute of Pharmacology and Toxicology, Medical School, Second Neapolitan University, Naples, Italy
    J Chemother 7:50-4. 1995
    ..38, 8.14 +/- 2.23, 6.40 +/- 1.63, 4.06 +/- 0.99 and 0.45 +/- 0.27 microgram/g) were higher than that in BS (6.87 +/- 1.96, 6.54 +/- 1.84, 3.52 +/- 1.23, 1.56 +/- 0.92 and 0.23 +/- 0.19 microgram/ml).(ABSTRACT TRUNCATED AT 250 WORDS)..
  80. ncbi request reprint Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD
    M Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Respir Med 96:439-43. 2002
    ....
  81. ncbi request reprint Clinical pharmacokinetics of salmeterol
    Mario Cazzola
    Department of Respiratory Medicine, A Cardarelli Hospital, Naples, Italy
    Clin Pharmacokinet 41:19-30. 2002
    ..This is an important point, because it has been demonstrated that the systemic effects of salmeterol are more likely to occur with higher doses, which lead to approximately proportionally increased blood concentrations...
  82. ncbi request reprint Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma
    Alessandro Vatrella
    Section of Respiratory Diseases, Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy
    Pulm Pharmacol Ther 18:89-92. 2005
    ....
  83. ncbi request reprint Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease
    M Cazzola
    A Cardarelli Hospital, Division of Pneumology and Allergology, Naples, Italy
    Drugs 60:307-20. 2000
    ....
  84. ncbi request reprint Penetration of cefonicid into human lung tissue and lymph nodes
    M Cazzola
    Division of Occupational Pulmonary Disease and Respiratory Allergy, A Cardarelli Hospital, Naples, Italy
    Chemotherapy 36:325-31. 1990
    ..This finding was considered important, because it demonstrated that the high binding by plasma protein of cefonicid did not prevent it from entering lung tissue and fluids in useful quantities...
  85. ncbi request reprint Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline
    M Cazzola
    Institute of Pharmacology and Toxicology, 1st Medical School, Federico II University, Naples, Italy
    J Chemother 3:240-4. 1991
    ....
  86. ncbi request reprint Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance
    M Cazzola
    Division of Pneumology and Allergology and Respiratory Clinical Pharmacology Unit, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 13:249-56. 2000
    ....
  87. ncbi request reprint Teicoplanin with other drugs: possible pharmacological interactions
    M Angrisani
    Institute of Pharmacology and Toxicology, Medical School, II University, Naples, Italy
    J Chemother 5:22-6. 1993
    ..v.) on the rabbit. In conclusion our results documented that teicoplanin does not interfere with phenformin, glibenclamide, or sodium warfarin activities nor with aminophylline pharmacokinetics...
  88. doi request reprint It's about time--directing our attention toward modifying the course of COPD
    Mario Cazzola
    University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy
    Respir Med 102:S37-48. 2008
    ..In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy...
  89. pmc Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
    Andrea Rossi
    Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy
    Int J Chron Obstruct Pulmon Dis 3:521-9. 2008
    ..Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome...
  90. ncbi request reprint ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
    Maria Gabriella Matera
    Department of Experimental Medicine, Unit of Pharmacology, 2nd University of Naples, Naples, Italy
    Drugs 67:503-15. 2007
    ....
  91. ncbi request reprint [Adequate surrogate parameters in COPD studies]
    M Cazzola
    Dipartimento di Medicina, Interna, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Roma, Italy
    Dtsch Med Wochenschr 132:522-3. 2007
  92. ncbi request reprint Clinical pharmacokinetics of theophylline during co-treatment with ticarcillin plus clavulanic acid in patients suffering from acute exacerbation of chronic bronchitis
    M G Matera
    Institute of Pharmacology and Toxicology, Medical School, Second University, Naples, Italy
    J Chemother 5:233-6. 1993
    ..No influence of ticarcillin/clavulanic acid was detectable on the steady-state theophylline pharmacokinetics. It is concluded that both drugs can be administered concomitantly without any dosage adjustment of theophylline...
  93. ncbi request reprint Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy
    Drugs 65:1595-610. 2005
    ..Therefore, beta(2)-agonists must always be used with caution in patients with cardiopathies because these agents may precipitate the concomitant cardiac disease...
  94. ncbi request reprint Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, Antonio Cardarelli Hospital, Naples, Italy
    Chest 126:220-37. 2004
    ..All of these effects are very important because, despite recent advances in our understanding of COPD and its treatment, therapy remains suboptimal for a considerable number of patients...
  95. doi request reprint Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD
    Mario Cazzola
    Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Pulm Pharmacol Ther 22:177-82. 2009
    ....
  96. ncbi request reprint Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler
    Mario Cazzola
    Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Second University of Naples, Via del Parco Margherita 24, 80121 Naples, Italy
    Pulm Pharmacol Ther 16:105-9. 2003
    ..001) from 2-h levels. These results show that dose-dependent bronchodilatation of formoterol is maintained despite regular treatment...
  97. ncbi request reprint Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections
    M Cazzola
    A Cardarelli Hospital, Department of Respiratory Medicine, Naples, Italy
    Pulm Pharmacol Ther 14:367-81. 2001
    ....
  98. ncbi request reprint Effect of ketanserin, a new blocking agent of the 5-HT2 receptor, on airway responsiveness in asthma
    M Cazzola
    Department of Pulmonary Medicine, A Cardarelli Hospital, Naples, Italy
    Allergy 45:151-3. 1990
    ..The protective effect of intravenous ketanserin (0.14 mg/kg) was small, but significant...
  99. ncbi request reprint Cefaclor in the treatment of infective exacerbations of chronic bronchitis in cigarette smokers
    M Cazzola
    36th Division of Pneumology and Respiratory Allergy, A Cardarelli Hospital, Naples, Italy
    J Chemother 3:245-9. 1991
    ..Because of its excellent response rate, cefaclor is of particular value in the treatment of lower respiratory tract infections in cigarette smokers...
  100. ncbi request reprint Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD
    Mario Cazzola
    Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 16:197-201. 2003
  101. ncbi request reprint Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction
    Cecilia Calabrese
    Department of Cardio Thoracic and Respiratory Sciences, Second University of Naples, Monaldi Hospital, Via Bianchi, 80131 Naples, Italy
    Respir Med 100:1415-22. 2006
    ....